Search results
Results From The WOW.Com Content Network
Biogen said it will pay Reata $172.50 per share in cash, which represents a 58.9% premium to the stock's last closing price. Including debt, the deal values Reata at roughly $7.3 billion.
Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The Alzheimer’s treatment developer said Friday it will pay $172.50 in cash for each ...
May 22, 2024 at 9:00 AM. (Reuters) -Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its ...
Bioverativ Inc. Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. [3] Bioverativ competes with Baxalta (acquired by Shire Plc in 2016 [4] ), Pfizer and Novo Nordisk. [2] The company traded on the NASDAQ exchange under the ...
US $53.59 million (2018) [1] Owner. Biogen (2023–present) Website. www .reatapharma .com. Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Plano, Texas. Founded in 2002, it is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs, [2] which dually activate the antioxidative ...
Biogen stock is a component of several stock indices such as the S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB. [11] In May 2006, the company announced it would acquire cancer specialist, Conforma Therapeutics for $250 million. [12]
Generally speaking, pharmaceuticals are experiencing a mixed year. After a promising start where Biogen shares closed out January up more than 8%, the momentum quickly collapsed. It wasn’t until ...
Genzyme. Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics [2]) has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people ...